Literature DB >> 16193641

CD4+ T lymphocytes: a critical component of antitumor immunity.

Suzanne Ostrand-Rosenberg1.   

Abstract

Both prophylactic and therapeutic vaccines targeting a wide variety of cancers are being developed. Because of the potency of cell-mediated immunity, many vaccine strategies are focused on activating tumor-specific cytotoxic CD8+ T lymphocytes. CD4+ T lymphocytes are a key element in optimal activation of CD8+ T cells and in the maintenance of immune memory, and therefore their activation is critical for cancer vaccine efficacy. This article reviews the mechanisms by which CD4+ T cells facilitate tumor immunity and the vaccine strategies that enhance CD4+ T cell activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16193641

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  33 in total

Review 1.  Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.

Authors:  Laurence C Eisenlohr; Nancy Luckashenak; Sebastien Apcher; Michael A Miller; Gomathinayagam Sinnathamby
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

2.  The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.

Authors:  Emeline Ragonnaud; Peter Holst
Journal:  Ther Adv Vaccines       Date:  2013-05

3.  Combined influence of adjuvant therapy and interval after surgery on peripheral CD4(+) T lymphocytes in patients with esophageal squamous cell carcinoma.

Authors:  Yang Ling; Lieying Fan; Chunlei Dong; Jing Zhu; Yongping Liu; Yan Ni; Changtai Zhu; Changsong Zhang
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

4.  Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.

Authors:  Martin Grimm; Oliver Feyen; Heiko Hofmann; Peter Teriete; Thorsten Biegner; Adelheid Munz; Siegmar Reinert
Journal:  Tumour Biol       Date:  2015-10-16

5.  MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

Authors:  Swagatam Ray; Arvind Chhabra; Nitya G Chakraborty; Upendra Hegde; David I Dorsky; Thinle Chodon; Erika von Euw; Begonya Comin-Anduix; Richard C Koya; Antoni Ribas; James S Economou; Steven A Rosenberg; Bijay Mukherji
Journal:  Clin Immunol       Date:  2010-05-23       Impact factor: 3.969

6.  Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles.

Authors:  Rutika A Kokate; Sanjay I Thamake; Pankaj Chaudhary; Brittney Mott; Sangram Raut; Jamboor K Vishwanatha; Harlan P Jones
Journal:  Nanomedicine (Lond)       Date:  2015       Impact factor: 5.307

7.  Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.

Authors:  Oliver G Goldstein; Laela M Hajiaghamohseni; Shereen Amria; Kumaran Sundaram; Sakamuri V Reddy; Azizul Haque
Journal:  Cancer Immunol Immunother       Date:  2008-03-15       Impact factor: 6.968

Review 8.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

9.  Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.

Authors:  Zuqiang Liu; Hae S Noh; Janet Chen; Jin H Kim; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

10.  In vitro differentiation of adult bone marrow progenitors into antigen-specific CD4 helper T cells using engineered stromal cells expressing a notch ligand and a major histocompatibility complex class II protein.

Authors:  Bingbing Dai; Pin Wang
Journal:  Stem Cells Dev       Date:  2009-03       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.